Alzheimer's drug can 'slow disease' by eight years ⊕
Lecanemab is licensed for use in the UK but the spending watchdog deemed the benefits shown in clinical trials were 'too small' to justify the cost for the health service.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Lecanemab
since
auto-detected in 2 stories
2 days ago
9 months ago
Pressure grows on NHS to stump up for £60,000 'miracle' dementia drugs as drug watchdog reopens talks to give it the green light
Lecanemab and donanemab were hailed as 'the beginning of the end' of dementia last year, after studies showed they both slowed the progression of the memory-robbing illness.
page 1 of 1